Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $86.00

Posted by George Bondi on Jul 17th, 2026

Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) have received an average rating of “Hold” from the nine brokerages that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $86.00.

Several analysts recently issued reports on PCVX shares. Zacks Research downgraded Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Monday, July 6th.

Check Out Our Latest Report on Vaxcyte

Insider Buying and Selling at Vaxcyte

In related news, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $57.28, for a total transaction of $572,800.00. Following the completion of the sale, the chief financial officer directly owned 104,395 shares of the company’s stock, valued at approximately $5,979,745.60. This trade represents a 8.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50. Following the sale, the chief operating officer directly owned 156,760 shares in the company, valued at $8,830,290.80. This trade represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 75,448 shares of company stock valued at $4,091,197 over the last 90 days. 3.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Vaxcyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PCVX. Smartleaf Asset Management LLC grew its stake in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock worth $30,000 after acquiring an additional 600 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Vaxcyte by 33.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after purchasing an additional 184 shares during the last quarter. Allworth Financial LP boosted its holdings in Vaxcyte by 148.9% in the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its stake in Vaxcyte by 22,500.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Down 1.2%

PCVX opened at $56.04 on Friday. Vaxcyte has a 52-week low of $29.08 and a 52-week high of $65.00. The company has a 50 day moving average of $52.27 and a two-hundred day moving average of $54.22. The company has a market cap of $8.09 billion, a P/E ratio of -8.15 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period in the prior year, the business earned ($1.04) EPS. Research analysts anticipate that Vaxcyte will post -7.91 earnings per share for the current year.

Vaxcyte Company Profile

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.